<DOC>
	<DOCNO>NCT00792909</DOCNO>
	<brief_summary>The purpose study ass immune memory induce primary booster vaccination pneumococcal conjugate vaccine GSK1024850A first year life evaluation immune response follow vaccination booster dose pneumococcal conjugate vaccine GSK1024850A fourth year life ass immune response follow vaccination single dose pneumococcal conjugate vaccine GSK1024850A age-matched unprimed child . The study also aim ass antibody persistence fourth year life follow primary booster vaccination pneumococcal conjugate vaccine GSK1024850A first year life . The study also design evaluate immunogenicity term antibody response safety/reactogenicity term solicit unsolicited symptom serious adverse event follow 2-dose vaccination pneumococcal conjugate vaccine GSK1024850A fourth year life . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = 00307034 )</brief_summary>
	<brief_title>Vaccination Course Primed Children Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female , include , + 3646 month age time vaccination . For primed subject : complete full vaccination course GSK1024850A primary study ( NCT00307034 ) . Subjects investigator believe parent ( ) /guardian ( ) comply requirement protocol . Written inform consent obtain parent ( ) /guardian ( ) subject . Free obvious health problem establish medical history clinical examination enter study Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior vaccination . For primed subject : administration pneumococcal vaccine since end primary study ( NCT00307034 ) . For unprimed subject : previous vaccination pneumococcal vaccine . Administration immunoglobulins and/or blood product less 6 month prior vaccination plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History reaction allergic disease likely exacerbate component study vaccine . Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>36 Months</minimum_age>
	<maximum_age>46 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>